Agendia Announces First Patient Enrolled in DEBRA Trial Using MammaPrint®
Agendia®, Inc. , announced today that the first patient to use MammaPrint® as an enrollment biomarker for the DEBRA Trial is to be enrolled.
- Agendia®, Inc. , announced today that the first patient to use MammaPrint® as an enrollment biomarker for the DEBRA Trial is to be enrolled.
- The Phase III NRG Oncology De-Escalation of Breast Radiation (DEBRA) Trial ( NCT04852887 ) is a clinical study looking at safely reducing the use of breast radiation after lumpectomy for people with low-risk, early-stage breast cancer.
- “With the first patient of this study being enrolled using MammaPrint, we look forward to participating in the development of a new path towards more precise, proactive treatment planning for early-stage breast cancer.”
To learn more about the DEBRA Trial and enrollment criteria, visit www.nrgoncology.org/DEBRA-Trial . - For more information about Agendia, visit www.agendia.com and follow Agendia on Facebook , Twitter , YouTube , and LinkedIn .